Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.36 |
| ▸ | GPR4 | P46093 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 3/20 | 0.34 |
| ▸ | CDK4 | P11802 | 3/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21267024 | 0.92 | CDK4 (0.37) | CXCR4GPR4HRH4DYRK2LYN | |
| SCHEMBL21414369 | 0.83 | CXCR4 (0.44) | CXCR4CCND1CDK4CDK6 | |
| SCHEMBL21414334 | 0.74 | CHRNB2 (0.53) | HRH4CCND1CDK4OPRL1CDK6 | |
| SCHEMBL21414366 | 0.73 | CXCR4 (0.45) | CXCR4 | |
| SCHEMBL20203429 | 0.72 | CXCR4 (0.47) | CXCR4CCND1CDK4CCND3 | |
| SCHEMBL21414378 | 0.71 | ALDH1A1 (0.49) | CCND1CDK4CDK6 | |
| SCHEMBL21414385 | 0.70 | LMNA (0.46) | — | |
| SCHEMBL18291648 | 0.68 | CXCR4 (0.57) | CXCR4CDK4CCND3 | |
| SCHEMBL21414381 | 0.68 | HRH3 (0.47) | — | |
| SCHEMBL21414349 | 0.68 | ALDH1A1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | CXCR4 1312/4885GPR4 2788/4885HRH4 2420/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CXCR4 1372/4885GPR4 2891/4885HRH4 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.